The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Equities research analysts at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for shares of ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 37,216 calls trading, 3x expected, and implied vol increasing almost 3 points to 39.30%. Jan-26 25 calls and May-25 43 calls are the ...

During a special ceremony, the mayor presented a proclamation to Cari Gallman, Executive Vice President of Corporate Affairs ...

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

As tariffs tanked stocks on Thursday, CNBC’s Jim Cramer believes investors should look to the same sectors that rose after ...

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...